Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study

Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study

Regorafenib, an oral multikinase inhibitor, has improved survival in metastatic colorectal cancer (mCRC) patients who have progressed on standard therapies. Our study aimed to evaluate prognostic factors influencing regorafenib treatment and assess the optimal dosing regimen in a real-life setting....

Full description

Bibliographic Details
Main Authors: Sabin Goktas Aydin, Engin Eren Kavak, Atakan Topcu, Ayberk Bayramgil, Fahri Akgul, Seda Kahraman, Musa Baris Aykan, Yunus Emre Altıntas, Kaan Helvaci, Yuksel Urun, Ahmet Bilici, Mesut Seker, Mehmet Ali Nahit Sendur, Omer Fatih Olmez, Ozgur Acikgoz, Irfan Cicin
Format: Article
Language:English
Published: Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2023-11-01
Series:Biomolecules & Biomedicine
Subjects:
Regorafenib
metastatic colorectal cancer (mCRC)
dose escalation
dose interruption
progression-free survival (PFS)
overall survival (OS)
Online Access:https://www.bjbms.org/ojs/index.php/bjbms/article/view/9253

Internet

https://www.bjbms.org/ojs/index.php/bjbms/article/view/9253

Similar Items